Key regions: Germany, United States, India, Japan, United Kingdom
The demand for Anti-Rheumatic Drugs in Southern Europe has been steadily increasing over the years.
Customer preferences: Patients in Southern Europe tend to prefer non-steroidal anti-inflammatory drugs (NSAIDs) over other types of anti-rheumatic drugs due to their effectiveness in reducing pain and inflammation. However, there has been a growing preference for biologic drugs due to their ability to target specific components of the immune system, resulting in better treatment outcomes.
Trends in the market: Spain and Italy are the largest markets for anti-rheumatic drugs in Southern Europe. The market has been witnessing a shift towards biologic drugs, with an increasing number of patients being prescribed these drugs. This trend is expected to continue due to the effectiveness of biologic drugs in treating rheumatoid arthritis and other autoimmune diseases.
Local special circumstances: The aging population in Southern Europe has been a major driver of the demand for anti-rheumatic drugs. As the population continues to age, the prevalence of rheumatoid arthritis and other autoimmune diseases is expected to increase. Additionally, the high prevalence of obesity and sedentary lifestyles in the region has also contributed to the demand for anti-rheumatic drugs.
Underlying macroeconomic factors: The economic downturn in Southern Europe has had a significant impact on the anti-rheumatic drugs market. The high cost of biologic drugs has resulted in many patients being unable to afford them, leading to a preference for cheaper alternatives such as NSAIDs. However, with the gradual recovery of the economy, it is expected that more patients will be able to afford biologic drugs, leading to an increase in demand. Additionally, the increasing focus on healthcare in the region is also expected to drive the growth of the anti-rheumatic drugs market in Southern Europe.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
